Leonard Schleifer, Regeneron president & CEO, discusses the FDA's approval of its cholesterol-lowering drug Praluent, and concerns over pricing the new drug. With Jeffrey Sonnenfeld, Yale School of Management.
Discussing safer alternatives to ibuprofen after the FDA warnings, with Dr. Devi Nampiaparampil, NYU School of Medicine. "All of the alternatives have risks," she explains.
The FDA gives restaurants more time to put calorie counts on their menus.
FDA Strengthens Heart Safety Warnings on Painkillers.
The FDA is strengthening its warnings about painkillers like ibuprofen, saying they do raise the risk of heart attack or stroke.
Novartis wins FDA approval for new combination drug Entresto to treat heart failure.
Animal health behemoth Zoetis was halted for volatility on Thursday.
The CEO of Medtronic talks new FDA approval and how to improve the health-care system.
Mount Sinai's CEO sees a "death spiral" could occur if the Supreme Court rules against the health insurance subsidies in Obamacare.
OraSure Technologies' test, which takes 20 minutes for results, could help stop the spread of Ebola in an outbreak.
Blue Bell identified the source of the listeria outbreak at its Oklahoma facility as one unsanitary room.
Regeneron's shares sank 4 percent despite a positive Food and Drug Administration recommendation on a cholesterol drug. What gives?
Ten so-called breakthrough drugs for cancers and chronic conditions will cost taxpayers big bucks.
CNBC's Meg Tirrell reports the FDA meets today and tomorrow to discuss and vote on recommendation for approval of new cholesterol drugs, Praluent and Repatha.
CNBC's Meg Tirrell reports on the woman's libido drug.
A drug to treat low female sexual desire should be approved with strict measures to ensure patients are aware of its risks, an FDA panel concluded.
The FDA is again considering approval for Fibanserin, "the female Viagra."
Get prepared to hit the treadmill after eating these calorie-laden dishes.
Texas-based Blue Bell Creameries was aware that it had listeria in an Oklahoma plant as early as 2013 but failed to act, says the FDA.
Traders are watching the iShares Nasdaq Biotechnology ETF for clues on whether a deeper stock market decline is on the horizon.